An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition
Status:
Not yet recruiting
Trial end date:
2022-07-22
Target enrollment:
Participant gender:
Summary
An open-label, randomized, single-dose, two-way crossover bioequivalence study to compare two
strengths (10 mg and 20 mg) of IMP4297 capsules in healthy Chinese subjects under fed
condition